Drug Profile
Zolunicant - Mindmed
Alternative Names: 18-MC; 18-MC HCL; 18-Methoxycoronaridine; MM-110; Zolunicant hydrochlorideLatest Information Update: 21 Jun 2023
Price :
$50
*
At a glance
- Originator Mindmed
- Class Antiprotozoals; Azepines; Carboxylic acids; Drug withdrawal therapies; Esters; Indole alkaloids; Pyridones; Small molecules
- Mechanism of Action Alpha3beta4 nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Opioid-related disorders
- Phase I Substance-related disorders
- Discontinued Leishmaniasis
Most Recent Events
- 21 Jun 2023 Discontinued - Phase-I for Leishmaniasis (In volunteers) in Brazil (PO) (Mindmed pipeline, June 2023)
- 20 Jun 2023 Zolunicant - Mindmed is available for licensing as of 20 Jun 2023. https://mindmed.co/
- 20 Jun 2023 Phase-II clinical trials in Opioid-related disorders (PO) (Mindmed pipeline, June 2023)